Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.80 |
| ▸ | CDK1 | P06493 | 6/20 | 0.77 |
| ▸ | CDK2 | P24941 | 5/20 | 0.77 |
| ▸ | SMG1 | Q96Q15 | 3/20 | 0.77 |
| ▸ | CDK4 | P11802 | 3/20 | 0.77 |
| ▸ | MAPT | P10636 | 2/20 | 0.77 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.77 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.77 |
| ▸ | CCND1 | P24385 | 2/20 | 0.77 |
| ▸ | CDK7 | P50613 | 2/20 | 0.77 |
| ▸ | CCNH | P51946 | 2/20 | 0.77 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.77 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.77 |
| ▸ | MTOR | P42345 | 2/20 | 0.77 |
| ▸ | NPC1 | O15118 | 1/20 | 0.77 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.77 |
| ▸ | XBP1 | P17861 | 1/20 | 0.77 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.77 |
| ▸ | HTT | P42858 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6107401 | 0.94 | CDK1 (0.81) | CSNK2A1CDK1CDK2SMG1CDK4 | |
| SCHEMBL6107344 | 0.91 | CSNK2A1 (0.77) | CSNK2A1CDK1CDK2SMG1CDK4 | |
| SCHEMBL6107651 | 0.89 | CSNK2A1 (1.00) | CSNK2A1CDK1CDK2SMG1CDK4 | |
| SCHEMBL6094407 | 0.89 | CDK1 (0.88) | CSNK2A1CDK1CDK2SMG1CDK4 | |
| SCHEMBL29385808 | 0.87 | CDK1 (1.00) | CSNK2A1CDK1CDK2SMG1CDK4 | |
| SCHEMBL30782585 | 0.87 | CDK1 (1.00) | CSNK2A1CDK1CDK2SMG1CDK4 | |
| SCHEMBL1574530 | 0.87 | CDK1 (1.00) | CSNK2A1CDK1CDK2SMG1CDK4 | |
| SCHEMBL7813303 | 0.87 | CDK1 (0.96) | CSNK2A1CDK1CDK2SMG1CDK4 | |
| SCHEMBL29397852 | 0.87 | CDK1 (1.00) | CSNK2A1CDK1CDK2SMG1CDK4 | |
| SCHEMBL7804352 | 0.86 | CDK1 (0.94) | CSNK2A1CDK1CDK2SMG1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0672042-B1 | PHARMACOLOGICALLY ACTIVE PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 2006-05-03 | — | — | EP | claimed |
| US-5705502-A | Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof | NOVARTIS CORPORATION (US) | 1998-01-06 | — | — | US | claimed |
| EP-0672042-A1 | PHARMACOLOGICALLY ACTIVE PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Novartis AG (CH) | 1995-09-20 | — | — | EP | claimed |
| WO-1995009851-A1 | PHARMACOLOGICALLY ACTIVE PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | CIBA-GEIGY AG (CH) | 1995-04-13 | — | — | WO | claimed |
| US-7109197-B2 | N-phenyl-4-(4-pyridyl)-2-pyrimidineamine derivatives | SYNGENTA CROP PROTECTION, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| EP-0672042-B1 | PHARMACOLOGICALLY ACTIVE PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 2006-05-03 | — | — | EP | disclosed |
| EP-1292190-B1 | N-PHENYL-4-(4-PYRIDYL)-2-PYRIMIDINEAMINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2005-08-24 | — | — | EP | disclosed |
| US-20030236256-A1 | N-phenyl-4-(4-pyridyl)-2-pyrimidineamine derivatives | SYNGENTA CROP PROTECTION, INC. | 2003-12-25 | — | — | US | disclosed |
| US-5705502-A | Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof | NOVARTIS CORPORATION (US) | 1998-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236256-A1 | N-phenyl-4-(4-pyridyl)-2-pyrimidineamine derivatives | HRH4, HRH3, HRH2 | CSNK2A1 3430/4885CDK1 2196/4885CDK2 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.